GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Allergy Therapeutics PLC (OTCPK:AGYTF) » Definitions » Gross Margin %

Allergy Therapeutics (Allergy Therapeutics) Gross Margin % : 61.12% (As of Dec. 2023)


View and export this data going back to 2004. Start your Free Trial

What is Allergy Therapeutics Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Allergy Therapeutics's Gross Profit for the six months ended in Dec. 2023 was $25.98 Mil. Allergy Therapeutics's Revenue for the six months ended in Dec. 2023 was $42.50 Mil. Therefore, Allergy Therapeutics's Gross Margin % for the quarter that ended in Dec. 2023 was 61.12%.

Warning Sign:

Allergy Therapeutics PLC gross margin has been in long-term decline. The average rate of decline per year is -5%.


The historical rank and industry rank for Allergy Therapeutics's Gross Margin % or its related term are showing as below:

AGYTF' s Gross Margin % Range Over the Past 10 Years
Min: 52.54   Med: 72.81   Max: 75.11
Current: 52.54


During the past 13 years, the highest Gross Margin % of Allergy Therapeutics was 75.11%. The lowest was 52.54%. And the median was 72.81%.

AGYTF's Gross Margin % is ranked better than
60.4% of 990 companies
in the Drug Manufacturers industry
Industry Median: 46.8 vs AGYTF: 52.54

Allergy Therapeutics had a gross margin of 61.12% for the quarter that ended in Dec. 2023 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Allergy Therapeutics was -5.00% per year.


Allergy Therapeutics Gross Margin % Historical Data

The historical data trend for Allergy Therapeutics's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allergy Therapeutics Gross Margin % Chart

Allergy Therapeutics Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 75.07 74.17 73.79 68.03 55.79

Allergy Therapeutics Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 73.74 56.48 64.62 37.91 61.12

Competitive Comparison of Allergy Therapeutics's Gross Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Allergy Therapeutics's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Allergy Therapeutics's Gross Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Allergy Therapeutics's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Allergy Therapeutics's Gross Margin % falls into.



Allergy Therapeutics Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Allergy Therapeutics's Gross Margin for the fiscal year that ended in Jun. 2023 is calculated as

Gross Margin % (A: Jun. 2023 )=Gross Profit (A: Jun. 2023 ) / Revenue (A: Jun. 2023 )
=42 / 75.236
=(Revenue - Cost of Goods Sold) / Revenue
=(75.236 - 33.26) / 75.236
=55.79 %

Allergy Therapeutics's Gross Margin for the quarter that ended in Dec. 2023 is calculated as


Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=26 / 42.496
=(Revenue - Cost of Goods Sold) / Revenue
=(42.496 - 16.521) / 42.496
=61.12 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Allergy Therapeutics  (OTCPK:AGYTF) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Allergy Therapeutics had a gross margin of 61.12% for the quarter that ended in Dec. 2023 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Allergy Therapeutics Gross Margin % Related Terms

Thank you for viewing the detailed overview of Allergy Therapeutics's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Allergy Therapeutics (Allergy Therapeutics) Business Description

Traded in Other Exchanges
Address
Dominion Way, Worthing, West Sussex, GBR, BN14 8SA
Allergy Therapeutics PLC is active in the healthcare sector in the United Kingdom. It is a pharmaceutical company mainly engaged in the treatment and prevention of allergies with aluminum-free products. The company's geographical segment includes Central Europe; Southern Europe and the Rest of the World. It generates maximum revenue from Central Europe which includes Germany and other countries.

Allergy Therapeutics (Allergy Therapeutics) Headlines